The future of nanomedicine in optimising the treatment of inflammatory bowel disease

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.e42.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996–1006.
   PubMed Web of Science ®Google Scholar
• Darr U, Khan N. Treat to target in inflammatory bowel disease: an updated review of literature [journal article]. Curr Treat Options Gastro. 2017;15:116–125.
   PubMedGoogle Scholar
• Dave M, Loftus EV. Mucosal healing in inflammatory bowel disease—a true paradigm of success? Gastroenterol Hepatol. 2012;8:29–38.
   PubMedGoogle Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol. 2011;17:3467–3478.
   PubMed Web of Science ®Google Scholar
• Nitzan O, Elias M, Peretz A, et al. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22:1078–1087.
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
   PubMed Web of Science ®Google Scholar
• Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol. 2016;9:59–70.
   PubMed Web of Science ®Google Scholar
• Nielsen OH. New strategies for treatment of inflammatory bowel disease [review]. Front Med (Lausanne). 2014;1:3.
   PubMedGoogle Scholar
• Rogler G. Top-down or step-up treatment in Crohn's disease? Dig Dis. 2013;31:83–90.
   PubMed Web of Science ®Google Scholar
• Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113–123.
   PubMed Web of Science ®Google Scholar
• Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893–903.
   PubMedGoogle Scholar
• Su JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn's disease: a systematic review and meta-analysis. J Dig Dis. 2015;16:58–66.
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des, Dev Ther. 2011;5:185–210.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. New steroids for IBD: progress report. Gut. 2002;51:182–183.
   PubMed Web of Science ®Google Scholar
• Prantera C, Marconi S. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol. 2013;6:137–156.
   PubMed Web of Science ®Google Scholar
• Farrell R, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339–346.
   PubMed Web of Science ®Google Scholar
• Gómez-Gómez GJ, Masedo Á, Yela C, et al. Current stage in inflammatory bowel disease: what is next? World J Gastroenterol. 2015;21:11282–11303.
   PubMed Web of Science ®Google Scholar
• Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol. 2014;20:3146–3152.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (London, England). 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Higgins PDR. The IBD drug pipeline - ready to deliver? [inflammatory bowel disease]. Am J Gastroenterol. 2014;109:1052–1054.
   PubMed Web of Science ®Google Scholar
• Allen PB, Lindsay H, Tham TCK. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Lautenschläger C, Schmidt C, Fischer D, et al. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014;71:58–76.
   PubMed Web of Science ®Google Scholar
• Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery – a review. Pharm Sci Technol Today. 2000;3:138–145.
   PubMedGoogle Scholar
• Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS Pharm Sci Tech. 2015;16:731–741.
   PubMed Web of Science ®Google Scholar
• Hua S, Marks E, Schneider JJ, et al. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015;11:1117–1132.
   PubMed Web of Science ®Google Scholar
• Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010;25:79–87.
   PubMedGoogle Scholar
• Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease [journal article]. Dig Dis Sci. 1998;43:702–705.
   PubMed Web of Science ®Google Scholar
• Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48:571–577.
   PubMed Web of Science ®Google Scholar
• Rana SV, Sharma S, Malik A, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease [journal article]. Dig Dis Sci. 2013;58:2594–2598.
   PubMed Web of Science ®Google Scholar
• Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J Control Release. 2016;240:504–526.
   PubMed Web of Science ®Google Scholar
• Barkas F, Liberopoulos E, Kei A, et al. Electrolyte and acid-base disorders in inflammatory bowel disease. Ann Gastroenterol 2013;26:23–28.
   PubMedGoogle Scholar
• Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8:2101–2141.
   PubMed Web of Science ®Google Scholar
• Mudshinge SR, Deore AB, Patil S, et al. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J. 2011;19:129–141.
   PubMed Web of Science ®Google Scholar
• Bregoli L, Movia D, Gavigan-Imedio JD, et al. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine. 2016;12:81–103.
   PubMed Web of Science ®Google Scholar
• Ramtoola Z, Lyons P, Keohane K, et al. Investigation of the interaction of biodegradable micro- and nanoparticulate drug delivery systems with platelets. J Pharm Pharmacol. 2011;63:26–32.
   PubMed Web of Science ®Google Scholar
• Si X-Y, Merlin D, Xiao B. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World J Gastroenterol. 2016;22:7718–7726.
   PubMed Web of Science ®Google Scholar
• McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci. 1998;6:153–163.
   PubMed Web of Science ®Google Scholar
• Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed 2012;7:5577–5591.
   PubMed Web of Science ®Google Scholar
• Yameen B, Choi WI, Vilos C, et al. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release. 2014;190:485–499.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Tang BC, Whitehead KA, et al. Managing diabetes with nanomedicine: challenges and opportunities [review]. Nat Rev Drug Discov. 2015;14:45–57.
   PubMed Web of Science ®Google Scholar
• Bergin IL, Witzmann FA. Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. Int J Biomed Nanosci Nanotechnol. 2013;3:163–210.
   PubMedGoogle Scholar
• Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86:215–223.
   PubMed Web of Science ®Google Scholar
• Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615–627.
   PubMed Web of Science ®Google Scholar
• Coco R, Plapied L, Pourcelle V, et al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440:3–12.
   PubMed Web of Science ®Google Scholar
• Youshia J, Lamprecht A. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Expert Opin Drug Deliv. 2016;13:281–294.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18:788–793.
   PubMed Web of Science ®Google Scholar
• Thakral S, Thakral NK, Majumdar DK. Eudragit: a technology evaluation. Expert Opin Drug Deliv. 2013;10:131–149.
   PubMed Web of Science ®Google Scholar
• Naeem M, Choi M, Cao J, et al. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Dev Ther. 2015;9:3789–3799.
   PubMed Web of Science ®Google Scholar
• Ali H, Weigmann B, Neurath MF, et al. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release. 2014;183:167–177.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Lautenschlaeger C, Collnot EM, et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J Control Release. 2013;165:139–145.
   PubMed Web of Science ®Google Scholar
• Lautenschlager C, Schmidt C, Lehr CM, et al. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm. 2013;85:578–586.
   PubMed Web of Science ®Google Scholar
• Pertuit D, Moulari B, Betz T, et al. 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release. 2007;123:211–218.
   PubMed Web of Science ®Google Scholar
• Moulari B, Pertuit D, Pellequer Y, et al. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 2008;29:4554–4560.
   PubMed Web of Science ®Google Scholar
• Tang H, Xiang D, Wang F, et al. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice. Mol Med Rep. 2017;15:1117–1122.
   PubMed Web of Science ®Google Scholar
• Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm. 2009;72:1–8.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm. 2013;454:775–783.
   PubMed Web of Science ®Google Scholar
• Vafaei SY, Esmaeili M, Amini M, et al. Self-assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohydr Polym. 2016;144:371–381.
   PubMed Web of Science ®Google Scholar
• Dianzani C, Foglietta F, Ferrara B, et al. Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: effects in an in vivo model. World J Gastroenterol. 2017;23:4200–4210.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005;315:196–202.
   PubMed Web of Science ®Google Scholar
• Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm. 2006;316:138–143.
   PubMed Web of Science ®Google Scholar
• Guada M, Beloqui A, Alhouayek M, et al. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease. Int J Pharm. 2016;503:196–198.
   PubMed Web of Science ®Google Scholar
• Melero A, Draheim C, Hansen S, et al. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J Pharm Biopharm. 2017;119:361–371.
   PubMed Web of Science ®Google Scholar
• Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterol. 2014;146:1289–1300.e1–19.
   PubMed Web of Science ®Google Scholar
• Nguyen HTT, Dalmasso G, Torkvist L, et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J Clin Invest. 2011;121:1733–1747.
   PubMed Web of Science ®Google Scholar
• Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15:1200–1209.
   PubMed Web of Science ®Google Scholar
• Tahara K, Samura S, Tsuji K, et al. Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials. 2011;32:870–878.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015;372:1104–1113.
   PubMed Web of Science ®Google Scholar
• Vegter S, Tolley K, Wilson Waterworth T, et al. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther. 2013;38:284–293.
   PubMed Web of Science ®Google Scholar
• Muheem A, Shakeel F, Jahangir MA, et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J. 2016;24:413–428.
   PubMed Web of Science ®Google Scholar
• Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138:843–853.e1–2.
   PubMed Web of Science ®Google Scholar
• Theiss AL, Laroui H, Obertone TS, et al. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis. 2011;17:1163–1176.
   PubMed Web of Science ®Google Scholar
• Takedatsu H, Mitsuyama K, Torimura T. Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease. World J Gastroenterol. 2015;21:11343–11352.
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621.
   PubMed Web of Science ®Google Scholar
• Wilson DS, Dalmasso G, Wang L, et al. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nature Mater. 2010;9:923–928.
   PubMed Web of Science ®Google Scholar
• Laroui H, Viennois E, Xiao B, et al. Fab'-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release. 2014;186:41–53.
   PubMed Web of Science ®Google Scholar
• Kriegel C, Amiji MM. Dual TNF-α/cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin Trans Gastroenterol. 2011;2:e2.
   PubMedGoogle Scholar
• Laroui H, Geem D, Xiao B, et al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol Ther. 2014;22:69–80.
   PubMed Web of Science ®Google Scholar